#Hematology Nivolumab-AVD Versus Brentuximab Vedotin–AVD in Older Patients With Advanced-Stage Classic #Hodgkin #Lymphoma Enrolled on S1826 | ⁦Journal of Clinical Oncology⁩ Journal of Clinical Oncology #lymsm #geriheme ascopubs.org/doi/10.1200/JC…

Fascinating talk by DeSelm - CAR-T worked less well on tumours not irradiated. Irradiation reduces phosphethalamine which increases DAG in CAR-T, promoting cell function. #ICML2025

Kuhnl - impressive results from UK RESTART protocol looking at RT as bridge or as consolidation. ESP impressive in those who needed systemic bridging and who had inadequate response to CAR. #ICML2025

Our new standard for classical Hodgkin lymphoma >60 years in Sweden.

David Russler-Germain, MD/PhD - fantastic work on LymphomaMAPs (microenv of DLBCL) looking at prognosis of CAR-T therapy. Showed that TEX archetype associated with signif worse outcome. Assoc with • exhausted T-cells • super-activated macrophages. #ICML18

Sancho et al - POLARGO. • RGemOx vs Pola-RGemOx R/R DLBCL • 2L+ DLBCL (no ASCT eligible if 2L) • OS primary EP: signif adv 12.5mo vs 19.5mo • PFS & CMR rate better • tox modest - ⬆️ infn & PN • no effect of cell of origin Interesting but ? value if 1L PolaRCHP #18ICML

Ahmed et al - EBV & cHL subtype in S1826 study • EBV+ pts do much better with NAVD compared with BV-AVD (EBV- also do better but less marked) • non-NS histology also benefited more from NAVD. Biology is important! #lymsm #18ICML #ICML25

Best slide of #18ICML #ICML2025! COO/Dark signature #DLBCL. Magisterial Gianni Bonadonna lecture by Dr. David Scott from BCC. It was like a “Great Gig in the sky” realizing how far we have achieved in this #lymphoma. Only a matter of “Time” to be out of the eclipse “….

Uppsala posters at 18-ICML: Neutrophil Extracellular Traps (NETs) in DLBCL and cHL, and CNS-lymphoma diagnosis w proteomics.

Fujimoto et al - Allo / auto in ENKT? Japanese data. • if in CR, ASCT appear superior to allo • if in PR, allo appears preferable • no impact on source of allo cells I normally allo these pts in CR1 so potentially practise changing. #18ICML #ICML25 #lymsm

The big debate 1: Ferreri vs Cwynarski: CNS-prophylaxis or not. No is the answer.

The big debate 3: Smith vs Nowakowski: Is Pola-R-CHP the new standard for all DLBCL? No.

Fertility data from HD21, just published. Compared w eBEACOPP, BrECADD led to better gonadal recovery and higher parenthood rates. Support BrECADD as preferred first-line treatment for younger pts w advanced Hodgkin lymphoma. pdf.sciencedirectassets.com/272203/AIP/1-s…

Jag skriver om paradoxen att Sverige satsar miljarder på det militära försvaret, medan regionerna sparar miljarder på en sjukvård som är gravt underdimensionerad redan i fredstid. En god beredskap behöver mer än ett ben att stå på. svd.se/a/1MlpWQ/danie…

En försvarssatsning utan en samtidig satsning på vården är en ofullständig och farlig strategi. Vi måste investera i en sjukvård som är stark i både fred och kris, skriver överläkaren Daniel Molin. svd.se/a/1MlpWQ/danie…

HD21, BrECADD for Hodgkin patients >60 years. PFS 91.5% at 2 years. We use mostly N-AVD for these patients but BrECADD can be an effective alternative for fit patients, with shorter treatment duration and less doxorubicine. ascopubs.org/doi/10.1200/JC…

New textbook in haematology. Unfortunately only available in Swedish.

Hot news - Epcor + R2 superior to R2 in RR follicular lymphoma. Overall response and PFS (HR 0.21). Hoping for a quick license and NICE approval. #lymsm

Survival after incidental vs symptomatic FL: - 908 pts, 29% incidental - incidental: more early stage & normal LDH - no diff in EFS, lymphoma-specific survival, or OS between groups We can answer the "what if this was picked up earlier" question! #lymsm nature.com/articles/s4140…

Happy that part 2 of the BVB study for older Hodgkin patients is published. A fruitful collaboration between the Nordic lymphoma group and the German Hodgkin study group, that hopefully will be followed by more. onlinelibrary.wiley.com/doi/10.1002/he…